Werewolf Therapeutics, Inc. (HOWL)Healthcare | Biotechnology | Watertown, United States | NasdaqGS
0.34 USD
-0.06
(-15.261%) ⇩
(July 13, 2026, 4 p.m.
EDT)
After hours: 0.34 |
Hot Take ↕ | July 11, 2026, 3:35 a.m. EDT
The investment case for Werewolf Therapeutics is currently broken by a catastrophic multi-year decline and a complete lack of financial viability. The stock has erased over 92% of its value since 2021, with four consecutive years of negative annual returns, signaling a deep structural deterioration in the business. Fundamentally, the company is burning cash aggressively with negative free cash flow and a massive debt load relative to its tiny market cap, while offering zero dividend income. The technical picture is equally grim, trading well below its 50-day and 200-day moving averages. While analysts have issued a 'strong buy' rating with a $7 target, this appears to be a theoretical valuation based on potential future success rather than current reality, as the stock lacks the revenue growth or profitability to support such a premium. Options activity confirms this pessimism, with traders buying deep out-of-the-money puts to bet on further collapse rather than calling for a recovery. Until there is concrete evidence of a clinical trial breakthrough or a successful capital raise to address the burn rate, this remains a high-risk speculative vehicle with no margin of safety. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.463880 |
| AutoETS | 0.482537 |
| AutoTheta | 0.484358 |
| AutoARIMA | 0.501819 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 32% |
| H-stat | 5.54 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.081 |
| Excess Kurtosis | -0.44 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 308.564 |
| Market Cap | 16,595,813 |
| Forward P/E | -0.34 |
| Beta | 0.30 |
| Website | https://werewolftx.com |
As of July 11, 2026, 3:35 a.m. EDT: Speculators are overwhelmingly positioning for downside protection rather than upside participation. Call volume is negligible across all expirations, while put activity is concentrated in the nearest expiration (July 17) with significant open interest at strikes far above the current price ($5.00 and $7.50). This heavy out-of-the-money put positioning suggests a strong expectation of a further decline or a 'double the money' scenario, indicating that the market views the current price as highly vulnerable.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.6875969 |
| Address1 | 200 Talcott Ave |
| Address2 | 2nd Floor |
| All Time High | 23.99 |
| All Time Low | 0.27 |
| Ask | 0.4357 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 1,100,480 |
| Average Daily Volume3 Month | 660,050 |
| Average Volume | 660,050 |
| Average Volume10Days | 1,100,480 |
| Beta | 0.298 |
| Bid | 0.2841 |
| Bid Size | 2 |
| Book Value | 0.251 |
| City | Watertown |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.3415 |
| Current Ratio | 1.265 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 0.419 |
| Day Low | 0.3343 |
| Debt To Equity | 308.564 |
| Display Name | Werewolf Therapeutics |
| Earnings Timestamp | 1,778,184,000 |
| Earnings Timestamp End | 1,778,184,000 |
| Earnings Timestamp Start | 1,778,184,000 |
| Ebitda | -50,046,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.156 |
| Enterprise Value | 7,796,813 |
| Eps Current Year | -1.27 |
| Eps Forward | -0.99 |
| Eps Trailing Twelve Months | -1.21 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.45734 |
| Fifty Day Average Change | -0.11583999 |
| Fifty Day Average Change Percent | -0.25329074 |
| Fifty Two Week Change Percent | -68.75969 |
| Fifty Two Week High | 2.38 |
| Fifty Two Week High Change | -2.0385 |
| Fifty Two Week High Change Percent | -0.8565126 |
| Fifty Two Week Low | 0.27 |
| Fifty Two Week Low Change | 0.0715 |
| Fifty Two Week Low Change Percent | 0.26481482 |
| Fifty Two Week Range | 0.27 - 2.38 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,619,789,400,000 |
| Float Shares | 47,914,518 |
| Forward Eps | -0.99 |
| Forward P E | -0.3449495 |
| Free Cashflow | -30,912,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 14 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Gross Profits | -33,911,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.056149997 |
| Held Percent Institutions | 0.26709998 |
| Implied Shares Outstanding | 48,596,817 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-04-30 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Werewolf Therapeutics, Inc., a biopharmaceutical company, engages in the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer and other immune-mediated conditions. The company designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies through its proprietary PREDATOR platform. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; WTX-921, a conditionally activated IL-10 INDUKINE molecule for the treatment of inflammatory bowel disease and potentially other inflammatory diseases; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. In addition, it develops WTX-1011, a conditionally activated INDUCER T cell engager molecule that targets STEAP 1 for prostate cancer, as well as WTX-2022 that targets CDH6 for ovarian and kidney cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts. |
| Long Name | Werewolf Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 16,595,813 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_560735713 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -56,265,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 19,589,376 |
| Number Of Analyst Opinions | 1 |
| Open | 0.41 |
| Operating Cashflow | -51,941,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 617 952 0555 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 0.3415 |
| Post Market Time | 1,783,986,801 |
| Previous Close | 0.403 |
| Price Eps Current Year | -0.26889765 |
| Price Hint | 4 |
| Price To Book | 1.3605579 |
| Profit Margins | 0.0 |
| Quick Ratio | 1.206 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | -0.0615 |
| Regular Market Change Percent | -15.2605 |
| Regular Market Day High | 0.419 |
| Regular Market Day Low | 0.3343 |
| Regular Market Day Range | 0.3343 - 0.419 |
| Regular Market Open | 0.41 |
| Regular Market Previous Close | 0.403 |
| Regular Market Price | 0.3415 |
| Regular Market Time | 1,783,972,801 |
| Regular Market Volume | 1,047,021 |
| Return On Assets | -0.39069 |
| Return On Equity | -1.6189301 |
| Sand P52 Week Change | 0.20847368 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 48,596,817 |
| Shares Percent Shares Out | 0.0174 |
| Shares Short | 847,096 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 949,598 |
| Short Name | Werewolf Therapeutics, Inc. |
| Short Percent Of Float | 0.0211 |
| Short Ratio | 1.06 |
| Source Interval | 15 |
| State | MA |
| Symbol | HOWL |
| Target High Price | 7.0 |
| Target Low Price | 7.0 |
| Target Mean Price | 7.0 |
| Target Median Price | 7.0 |
| Total Cash | 46,450,000 |
| Total Cash Per Share | 0.956 |
| Total Debt | 37,651,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.21 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 0.859935 |
| Two Hundred Day Average Change | -0.518435 |
| Two Hundred Day Average Change Percent | -0.60287696 |
| Type Disp | Equity |
| Volume | 1,047,021 |
| Website | https://werewolftx.com |
| Zip | 2,472 |